Citigroup Inc Direxion Daily S&P Biotech Bea Transaction History

Citigroup Inc

  • $163 Billion
  • Q4 2024

A detailed history of Citigroup Inc transactions in Direxion Daily S&P Biotech Bea stock. As of the latest transaction made, Citigroup Inc holds 400 shares of LABD stock, worth $2,704. This represents 0.0% of its overall portfolio holdings.

Number of Shares
400
Previous 400 -0.0%
Holding current value
$2,704
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022
SELL
$15.83 - $35.31 $13,297 - $29,660
-840 Reduced 67.74%
400 $10,000
Q2 2022

Aug 10, 2022
BUY
$28.35 - $81.35 $3,969 - $11,389
140 Added 12.73%
1,240 $48,000
Q1 2022

May 12, 2022
SELL
$23.35 - $52.45 $7,005 - $15,735
-300 Reduced 21.43%
1,100 $39,000
Q3 2021

Nov 10, 2021
BUY
$17.17 - $26.91 $24,038 - $37,674
1,400 New
1,400 $30,000

Others Institutions Holding LABD

# of Institutions
28
Shares Held
2.45M
Call Options Held
1.07M
Put Options Held
144K
View Full List

About DIREXION DAILY S&P BIOTECH BEA

LABD Quotes by TradingView
  • Ticker LABD
  • Sector ETFs
  • Industry ETFs
More about LABD
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email